Akaza Hideyuki, Tsuruo Takashi, Saijo Nagahiro, Sone Saburo, Isonishi Seiji, Ohashi Yasuo, Noguchi Shinzaburo, Kurebayashi Junichi, Kakehi Yoshiyuki, Ishikawa Hideki, Blackledge George
Dept. of Urology, Institute of Clinical Medicine, University of Tsukuba.
Gan To Kagaku Ryoho. 2005 Oct;32(10):1499-506.
The 12 th Oncology Forum discussed the progress and future strategy of cancer prevention in Japan. The National Cancer Center has established a research center for screening focusing on the most common six cancer, stomach, lung, liver, colon, breast and uterus cancer. The program so far had a cumulative detection rate of 3.3%, which is high,and may reflect the selection of subjects. Screening and chemoprevention is also being investigated in prostate cancer, but the issues centre on how to make this widely available. High risk subjects can also be identified for breast cancer. Obesity and family history are especially important. In colorectal cancer studies are evaluating different diets, but general application is not yet possible and the infrastructure to implement any general screening and prevention does not exist. Development of pharmaceutical treatments for prevention is difficult because of the need for very safe treatments, and also because of the length of time needed to carry out studies. Overall, cancer prevention is still in evolution. New approaches are needed, and new infrastructure will be needed at a government level to implement this.
第12届肿瘤学论坛讨论了日本癌症预防的进展和未来战略。国立癌症中心设立了一个筛查研究中心,重点关注胃癌、肺癌、肝癌、结肠癌、乳腺癌和子宫癌这六种最常见的癌症。到目前为止,该项目的累积检出率为3.3%,这一比例较高,可能反映了受试者的选择情况。前列腺癌的筛查和化学预防也在进行研究,但问题集中在如何使其广泛应用。乳腺癌的高危人群也能够被识别出来。肥胖和家族病史尤为重要。在结直肠癌方面,研究正在评估不同的饮食,但目前还无法普遍应用,而且实施任何普遍筛查和预防的基础设施也不存在。由于需要非常安全的治疗方法,以及开展研究所需的时间长度,预防用药物治疗的开发很困难。总体而言,癌症预防仍在发展中。需要新的方法,并且在政府层面需要新的基础设施来实施这一点。